A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Camptothecin (Primary) ; Topotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 07 Aug 2017 Planned End Date changed from 1 May 2017 to 1 Nov 2017.
- 16 Jun 2016 Status changed from active, no longer recruiting to discontinued due to lack of activity and slow accrual.
- 18 Jun 2015 Planned End Date changed from 1 May 2016 to 1 May 2017 as reported by ClinicalTrials.gov record.